The MPP is a United Nations-backed group that works towards increasing access to life-saving medicines for low- and middle-income countries.
It facilitates the development of affordable generic versions of patented medicines.
The MPP has signed sub-licence agreements with India-based companies Eugia, Hetero, and Dr. Reddy’s Laboratories, as well as the Indonesian firm BrightGene.
These agreements allow these companies to produce generic versions of the cancer drug Nilotinib, originally patented by Novartis.
38
The sub-licence agreements aim to make cancer drugs more accessible and affordable for patients.
By allowing generic manufacturers to produce Nilotinib, the cost of the medication can be significantly reduced, making it more accessible to patients in low- and middle-income countries.
Nilotinib is used in the treatment of chronic myeloid leukaemia, a type of blood cancer.
The availability of generic versions of this drug allows more patients to access the treatment they need for this life-threatening condition.
39
The selected manufacturers in India and other middle-income countries have been granted the rights to produce generic versions of Nilotinib.
This promotes competition in the market, leading to lower prices and increased availability of the medication.
The sub-licence agreements are non-exclusive, allowing multiple manufacturers to produce and supply generic versions of Nilotinib.
This ensures a diverse supply of the medication, promoting availability and affordability in a wider range of territories.
40
The supply of generic Nilotinib by the licensed manufacturers is subject to local regulatory authorizations in the respective countries.
This ensures that the generic versions meet quality and safety standards before being made available to patients.
The availability of generic Nilotinib through the MPP's efforts provides an affordable treatment option for individuals diagnosed with chronic myeloid leukaemia in low- and middle-income countries.
This helps address the financial barriers that often limit access to life-saving medicines.
41
The licence agreement between the MPP and Novartis includes the opportunity to develop and supply generic versions of Nilotinib in seven middle-income countries.
This expands the reach of affordable cancer treatment options beyond low-income countries, benefiting a wider population.
COMMENTS